Abstract
Sodium oxybate (GHB, Xyrem, Jazz Pharmaceuticals) is used to treat cataplexy in patients with narcolepsy. We report the case of a middle aged, normo-ponderal narcoleptic woman without risk factors who developed reversible sleep apnea and objective sleepiness when treated by sodium oxybate, with an apnea-hypopnea index (AHI) of 19.7 on sodium oxybate and AHI 4.8 without treatment. Despite a subjective improvement in vigilance, mean sleep latency on MWT decreased from 21 minutes to 8 minutes on sodium oxybate.
Keywords:
Narcolepsy with cataplexy; periodic leg movements; sleep apnea; sodium oxybate.
MeSH terms
-
Adult
-
Cataplexy / complications
-
Cataplexy / diagnosis
-
Cataplexy / drug therapy*
-
Central Nervous System Depressants / adverse effects
-
Central Nervous System Depressants / therapeutic use
-
Dose-Response Relationship, Drug
-
Drug Administration Schedule
-
Female
-
Follow-Up Studies
-
Humans
-
Narcolepsy / complications
-
Narcolepsy / diagnosis
-
Narcolepsy / drug therapy*
-
Nocturnal Myoclonus Syndrome / complications
-
Nocturnal Myoclonus Syndrome / diagnosis
-
Nocturnal Myoclonus Syndrome / drug therapy*
-
Polysomnography / methods
-
Risk Assessment
-
Severity of Illness Index
-
Sleep Apnea Syndromes / chemically induced*
-
Sleep Apnea Syndromes / diagnosis
-
Sodium Oxybate / adverse effects*
-
Sodium Oxybate / therapeutic use
-
Treatment Outcome
Substances
-
Central Nervous System Depressants
-
Sodium Oxybate